文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

检测上皮性卵巢癌中的血管正常化。

Detecting vascular normalization in epithelial ovarian cancer.

作者信息

da S Mororó Jânio, Meira Débora D, Bizzo Solange M D, Altoé Lorena S C, Casotti Matheus C, Santana Gabriel M, Louro Luana S, Louro Thomas E S, Vicente Creuza R, de Araújo Bruno C, Groisman Sonia, de Carvalho Elizeu F, Louro Iúri D

机构信息

Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo (USP), São Paulo, Brazil.

Department of Biological Sciences, Universidade Federal Do Espírito Santo (UFES), Av. Fernando Ferrari, N. 514, Prédio Ciências Biológicas, Bloco A, Sala 106, Cep: 29.075-910, Vitória, Espírito Santo, Brazil.

出版信息

Med Oncol. 2025 Aug 3;42(9):401. doi: 10.1007/s12032-025-02929-5.


DOI:10.1007/s12032-025-02929-5
PMID:40754564
Abstract

Epithelial ovarian cancer (EOC) is highly angiogenic, making this tumor attractive, in the last 20 years, for analysis of clinical and biological functions of the VEGF family, relating altered expression with patient's clinical responses. Currently, analyzes and validations have yet to be made to relate vascular normalization with combinations of immune-, chemo- or radiotherapy. We review the main clinical analyses capable of identifying markers of vascular normalization including functional biomarkers (e.g., perfusion parameters by imaging techniques), molecular biomarkers (e.g., circulating protein levels and cfDNA), blood biomarkers, physiological markers and other approaches. Many markers cited here have not yet been analyzed in EOC but have shown promising results in tumors such as pancreatic and glioblastoma cancer, which share similarities with ovarian cancer. The methodologies presented have the advantage of not being invasive and immediately detecting vascular normalization, mainly using imaging techniques.

摘要

上皮性卵巢癌(EOC)具有高度血管生成性,在过去20年里,这使得该肿瘤成为分析血管内皮生长因子(VEGF)家族临床和生物学功能、将表达改变与患者临床反应相关联的热门对象。目前,尚未对血管正常化与免疫、化疗或放疗联合应用之间的关系进行分析和验证。我们综述了能够识别血管正常化标志物的主要临床分析方法,包括功能生物标志物(如通过成像技术测量的灌注参数)、分子生物标志物(如循环蛋白水平和游离DNA)、血液生物标志物、生理标志物及其他方法。这里提到的许多标志物尚未在EOC中进行分析,但在与卵巢癌有相似之处的胰腺癌和胶质母细胞瘤等肿瘤中已显示出有前景的结果。所介绍的方法具有非侵入性且能立即检测血管正常化的优点,主要是利用成像技术。

相似文献

[1]
Detecting vascular normalization in epithelial ovarian cancer.

Med Oncol. 2025-8-3

[2]
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Cochrane Database Syst Rev. 2022-9-26

[3]
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.

Clin Orthop Relat Res. 2025-1-1

[4]
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.

Cochrane Database Syst Rev. 2016-6-29

[5]
Optimal primary surgical treatment for advanced epithelial ovarian cancer.

Cochrane Database Syst Rev. 2011-8-10

[6]
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.

Clin Orthop Relat Res. 2024-12-1

[7]
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Cochrane Database Syst Rev. 2022-8-30

[8]
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Cochrane Database Syst Rev. 2013-7-9

[9]
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.

Oncol Rep. 2018-11-27

[10]
Prescription of Controlled Substances: Benefits and Risks

2025-1

本文引用的文献

[1]
Antidepressant effect of bright light therapy on patients with Alzheimer's disease and their caregivers.

Front Pharmacol. 2023-11-15

[2]
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.

J Clin Oncol. 2023-10-20

[3]
Preclinical evaluation of Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma.

Eur J Nucl Med Mol Imaging. 2023-8

[4]
Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion.

Front Oncol. 2022-12-1

[5]
Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis.

Diagnostics (Basel). 2023-3-9

[6]
Stereotactic Body Radiotherapy versus Surgery for Lung Metastases from Colorectal Cancer: Single-Institution Results.

Cancers (Basel). 2023-2-13

[7]
Folic acid-decorated alginate nanoparticles loaded hydrogel for the oral delivery of diferourylmethane in colorectal cancer.

Int J Biol Macromol. 2023-4-1

[8]
An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.

Gynecol Oncol. 2023-3

[9]
Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.

J Ovarian Res. 2022-6-3

[10]
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.

Mol Cancer Ther. 2022-4-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索